Overall | Current exposure | Recent exposure | Past exposure | No use | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Event | Number of outcome events | PY | Incidence* (95% CI) | Number of outcome events | PY | Incidence* (95% CI) | Number of outcome events | PY | Incidence* (95% CI) | Number of outcome events | PY | Incidence* (95% CI) | Number of outcome events | PY | Incidence* (95% CI) |
Hospitalisations | |||||||||||||||
Any | 11701 | 13291 | 88.0 (86.4 to 89.6) | 3110 | 4601 | 67.6 (65.2 to 70.0) | 599 | 788 | 76.0 (70.0 to 82.4) | 836 | 1074 | 77.8 (72.7 to 83.3) | 7156 | 6827 | 104.8 (102.4 to 107.3) |
AF | 3962 | 24761 | 16.0 (15.5 to 16.5) | 1358 | 8487 | 16.0 (15.2 to 16.9) | 233 | 1610 | 14.5 (12.7 to 16.5) | 215 | 2649 | 8.1 (7.1 to 9.3) | 2156 | 12015 | 17.9 (17.2 to 18.7) |
Mortality | 2858 | 31939 | 8.9 (8.6 to 9.3) | 396 | 11663 | 3.4 (3.1 to 3.7) | 361 | 2359 | 15.3 (13.8 to 17.0) | 440 | 3830 | 11.5 (10.4 to 12.6) | 1661 | 14086 | 11.8 (11.2 to 12.4) |
*Number of cases per 100 PY.
AF, atrial fibrillation; PY, person-years; VKA, vitamin K antagonists.